A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT
The lack of safe, effective, and simple short-course regimens (SCRs) for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment has significantly impeded TB control efforts in China. (Source: Trials)
Source: Trials - April 1, 2024 Category: General Medicine Authors: Jingtao Gao, Mengqiu Gao, Jian Du, Yu Pang, Gary Mao, Nacer Lounis, Nyasha Bakare, Yanxin Jiang, Ying Zhan, Yuhong Liu and Liang Li Tags: Study protocol Source Type: research
Novel six-month all oral treatment of pre-extensively drug-resistant tuberculosis in Canada: New treatment options present new implementation challenges
Can Commun Dis Rep. 2023 Jan 5;49(1):15-20. doi: 10.14745/ccdr.v49i01a04. eCollection 2023 Jan 5.ABSTRACTDrug-resistant tuberculosis (TB) is a major global health challenge in part because there are fewer effective treatments and these treatments have been prolonged and more toxic. The evidence base for more effective, shorter, standardized treatments is evolving rapidly. Herein, we report the first case of pre-extensively drug-resistant pulmonary TB treated with a novel six-month all oral bedaquiline, pretomanid and linezolid (BPaL) regimen in Canada. Recent clinical trial data supporting BPaL therapy is presented in the ...
Source: Can Commun Dis Rep - March 29, 2024 Category: Infectious Diseases Authors: William Connors Cesilia Nishi Inna Sekirov Victoria Cook James Johnston Source Type: research
Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling
ConclusionsThe whole-body PBPK model for bedaquiline and M2 predicted unbound concentrations in brain to be significantly lower than the unbound concentrations in the lung at clinically relevant doses. Our findings suggest that bedaquiline may result in relatively inferior efficacy against drug-resistant TBM when compared with efficacy against drug-resistant pulmonary TB. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 26, 2024 Category: Drugs & Pharmacology Source Type: research
Treating drug-resistant tuberculosis in an era of shorter regimens: Insights from rural South Africa
CONCLUSION: In a rural context, treating DR-TB amid limited resources and a high burden of HIV co-infection, we found that after considering controls, a short regimen was no different to a longer regimen in terms of success or mortality. Therefore, by alleviating burdens on multiple stakeholders, a short regimen is likely to be favourable for rural patients, clinicians, and healthcare systems. Besides other previously described correlates of outcomes, HIV viraemia emerged as a novel marker for reliably predicting poor outcomes in DR-TB with HIV co-infection, and a pragmatic target for intervention.PMID:38525642 | DOI:10.71...
Source: South African Medical Journal - March 25, 2024 Category: African Health Authors: J-D K Lotz J Porter H Conradie T Boyles B Gaunt S Dimanda D Cort Source Type: research
